"Clinical trials are, by almost any measure, one of the most information-intensive processes in modern medicine, and one of the least efficiently managed. A single Phase III trial can generate data across dozens of sites, hundreds of variables, and multiple regulatory frameworks simultaneously."
"The software tools that research teams use to manage this complexity were largely designed in an earlier era, when the primary goal was storage rather than intelligence."
"Rivia announced today that it has raised €13 million in a new funding round to expand what it describes as an agentic data engine, a system in which AI agents actively surface insights, flag anomalies, and help coordinate the operational layer of a trial, rather than simply storing and visualising data."
Rivia, a Zurich-based startup founded in 2022, secured €13 million in funding to develop an agentic data engine for clinical trials. Clinical trials generate massive amounts of fragmented data across multiple sites, variables, and regulatory frameworks, yet existing software tools were designed primarily for storage rather than intelligence. The new funding represents a significant expansion from the company's €3 million seed round in June 2024. Rivia's solution addresses the core challenge of data fragmentation by unifying information from electronic data capture systems, patient wearables, laboratory instruments, and regulatory filings. The AI agents actively manage trial operations by surfacing insights, flagging anomalies, and coordinating operational tasks rather than simply storing and visualizing data.
Read at TNW | Startups-Technology
Unable to calculate read time
Collection
[
|
...
]